Cost-effectiveness evaluation of abiraterone in the treatment of patients with castration-resistant prostate cancer who previously received docetaxel.

被引：0
|
作者：
Chopra, Akhil
Gluck, Stefan
Montero, Alberto J.
Avancha, Kiran Kumar Venkata Raja
Lopes, Gilberto
机构：
[1] Johns Hopkins Singapore Int Med Ctr, Singapore, Singapore
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Miami Hosp & Clin, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Johns Hopkins Singapore, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15107
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [22] Effectiveness of abiraterone in the post-docetaxel setting on the survival of metastatic castration-resistant prostate cancer patients in quebec
    Hu, Jason
    Rocha, Joice
    Aprikian, Armen
    Vanhuyse, Marie
    Cury, Fabio
    Prevost, Noemie
    Dragomir, Alice
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 268 - 268
  • [23] Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer
    Sella, Avishay
    Sella, Tal
    Peer, Avivit
    Berger, Raanan
    Frank, Stephen Jay
    Gez, Eli
    Sharid, David
    Hayat, Henry
    Hanovich, Ekaterina
    Kovel, Svetlana
    Rosenbaum, Eli
    Neiman, Victoria
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [24] Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
    Zhong, Lixian
    Pon, Vickie
    Srinivas, Sandy
    Nguyen, Nicole
    Frear, Meghan
    Kwon, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Wilson, Leslie
    PLOS ONE, 2013, 8 (05):
  • [25] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY
    Thompson, Melissa
    Li, Tracy
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian
    He, Jianming
    Saadi, Ryan
    JOURNAL OF UROLOGY, 2014, 191 (04): : E810 - E810
  • [26] Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograft in vivo
    Nguyen, Holly M.
    Brown, Lisha G.
    Olson, Jessica L.
    Aftab, Dana T.
    Vessella, Robert L.
    Corey, Eva
    CANCER RESEARCH, 2014, 74 (19)
  • [27] RESULTS OF A DUTCH COST-EFFECTIVENESS MODEL OF RADIUM-223 IN COMPARISON TO CABAZITAXEL, ABIRATERONE, AND ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
    Gaultney, J.
    Baka, A.
    Leliveld-Kors, A.
    Noordzij, W.
    Wyndaele, D.
    De Meyer, C.
    VALUE IN HEALTH, 2015, 18 (07) : A459 - A459
  • [28] NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
    Dyer, Matthew
    Rinaldi, Fiona
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (08): : 762 - 763
  • [29] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [30] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
12345